UroGen Pharma to Report Third Quarter 2023 Financial Results on Tuesday, November 14, 2023
07 Novembro 2023 - 10:00AM
Business Wire
Conference Call and Webcast Scheduled for
Tuesday, November 14, 2023 at 10:00 AM ET
UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated
to developing and commercializing innovative solutions that treat
urothelial and specialty cancers, today announced that it will
report third quarter 2023 financial results on November 14, 2023,
at 8:00 AM EDT, prior to the open of the market. The announcement
will be followed by a live audio webcast and conference call at
10:00 AM Eastern Time.
A live public webcast of the earnings conference call can be
accessed on UroGen’s Investor Relations website. Following the live
webcast, a replay will be available on the site for approximately
30 days.
About UroGen Pharma Ltd.
UroGen is a biotech company dedicated to developing and
commercializing innovative solutions that treat urothelial and
specialty cancers because patients deserve better options. UroGen
has developed RTGel® reverse-thermal hydrogel, a proprietary
sustained release, hydrogel-based platform technology that has the
potential to improve therapeutic profiles of existing drugs.
UroGen’s sustained release technology is designed to enable longer
exposure of the urinary tract tissue to medications, making local
therapy a potentially more effective treatment option. JELMYTO®
(mitomycin) for pyelocalyceal solution and investigational
treatment UGN-102 (mitomycin) for intravesical solution for
patients with low-grade non-muscle invasive bladder cancer are
designed to ablate tumors by non-surgical means. UroGen is
headquartered in Princeton, NJ with operations in Israel. Visit
www.urogen.com to learn more or follow us on Twitter,
@UroGenPharma.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231107012900/en/
INVESTOR CONTACT: Vincent Perrone
vincent.perrone@urogen.com (609) 460-3588
MEDIA CONTACT: Cindy Romano Cindy.romano@urogen.com (609)
460-3583
UroGen Pharma (NASDAQ:URGN)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
UroGen Pharma (NASDAQ:URGN)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024
